Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
ARUP Laboratories, |
RCV003103714 | SCV001157514 | likely benign | not provided | 2023-04-10 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003234908 | SCV003934603 | uncertain significance | not specified | 2023-05-01 | criteria provided, single submitter | clinical testing | Variant summary: HBB c.186G>C (p.Lys62Asn) results in a non-conservative amino acid change located in the Globin (IPR000971) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251438 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.186G>C in individuals affected with Hemoglobinopathy and no experimental evidence demonstrating its impact on protein function have been reported. Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. One laboratory classified the variant as likely benign and another as VUS. Based on the evidence outlined above, the variant was classified as uncertain significance. |
OMIM | RCV000016379 | SCV000036647 | other | HEMOGLOBIN HIKARI | 2017-12-12 | no assertion criteria provided | literature only |